PRAC has started a review of Deanxit (flupentixol/melitracen) after reports of movement disorders and memory and thinking problems, some of which persisted after treatment stopped. The procedure is a useful case study in how safety referrals work.
What triggered the review
EMA’s highlights of the October 2026 PRAC meeting describe reports of movement disorders and cognitive problems, with some symptoms lasting after discontinuation. A referral lets the EU assess a concern that affects products or classes authorised nationally, so that the outcome can apply consistently across Member States.
How a pharmacovigilance referral proceeds
- Start. The Commission or a Member State triggers the procedure and a list of questions is issued to marketing authorisation holders.
- Assessment. PRAC evaluates the data and issues a recommendation.
- Opinion and decision. For nationally authorised products the recommendation goes to the CMDh, and for centrally authorised products to the CHMP, followed by implementation across the EU.
What holders should prepare
Companies with affected products should expect a request to submit data, including post-marketing case series, literature, exposure estimates and any information about persistence after treatment. Responses are time limited, so assembling evidence early is critical.
Outcomes can include
Possible outcomes range from no change to updated warnings, restrictions on use, additional risk minimisation or, in serious cases, suspension or withdrawal. Whatever the result, implementation in national product information and communication to prescribers follow within defined timelines.
How PQRA helps
PQRA helps marketing authorisation holders respond to referral lists of questions, compile safety evidence, and implement outcomes in national labelling and communication plans, including in Greece.


No responses yet